<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01643746</url>
  </required_header>
  <id_info>
    <org_study_id>CE 12.048</org_study_id>
    <nct_id>NCT01643746</nct_id>
  </id_info>
  <brief_title>Evaluation of Luminal Expansion Following Stenting of Femoro-popliteal Occlusive Disease</brief_title>
  <official_title>C-arm CT Evaluation of Luminal Expansion in Stenting Severe Femoro-popliteal Atherosclerotic Disease: Supera Versus LifeStent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Elizabeth II Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this trial is to compare prospectively stent opening of Supera (IDEV
      Technologies) versus a reference stent (LifeStent, Bard Medical) using C-arm CT. A secondary
      goal is to correlate stent opening with stent patency as documented by Doppler ultrasound at
      one year post implantation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    the study has never started. The sponsor has decided to not move forward
  </why_stopped>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent expansion</measure>
    <time_frame>At the completion of the intervention</time_frame>
    <description>Difference in minimal lumen diameter (MLD), minimal lumen area (MLA) and incomplete stent expansion as defined by C-arm CT between both groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stent patency</measure>
    <time_frame>1 year</time_frame>
    <description>Correlate stent opening with stent patency as documented by Doppler ultrasound at one year post implantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Femoropopliteal Stenosis</condition>
  <arm_group>
    <arm_group_label>Supera stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Supera stent is a novel interwoven nitinol stent design with high flexibility and radial strength. The radial force of the Supera stent is 4 times higher than comparable nitinol stent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LifeStent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LifeStent is likely the best reference nitinol stent for comparison because a low restenosis rate has been reported at 1 year with low target revascularization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supera Stent</intervention_name>
    <description>Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).</description>
    <arm_group_label>Supera stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Life Stent</intervention_name>
    <description>Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).</description>
    <arm_group_label>LifeStent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patient (or legally authorized representative) must give a written informed consent.

          -  Symptomatic peripheral-artery disease with moderate or severe intermittent
             claudication and failure of medical treatment (Rutherford stage 2,3) or chronic
             critical limb ischemia with pain while the patient is at rest (Rutherford stage 4) or
             chronic critical limb ischemia with ischemic ulcers (Rutherford stage 5, 6) and
             stenosis of more than 70 percent or occlusion of the ipsilateral superficial femoral
             artery and/or proximal popliteal artery with a target-lesion length of ≥ 8 and ≤ 20 cm
             and at least one patent (less than 50 percent stenosed) tibioperoneal runoff vessel
             (TASC A,B,C lesions)25. Proximal popliteal artery is defined as the popliteal artery
             above the joint line. The distal portion of the lesion should be located at least 4 cm
             above the joint line and the distal end of the stent 2 cm above the joint line.

          -  ABI ≤ 0.9 at rest. Toe-Brachial Index (TBI) may be used if ABI is inadequate.

          -  Lesion with a calcification percentage of at least 25% based on CTA evaluation (within
             6 months of patient enrolment)

        Exclusion Criteria:

          -  Acute critical limb ischemia

          -  Untreated inflow disease of the ipsilateral pelvic arteries (more than 50 percent
             stenosis or occlusion).

          -  Renal failure, creatinine clearance &lt; 50 µmol /l

          -  Severe allergy to iodine contrast

          -  Patients with uncorrected bleeding disorders or patients who cannot receive
             anticoagulation or antiplatelet aggregation therapy

          -  Lesions &lt; 8 and &gt; 20 cm in length

          -  Calcification volume of less than 25%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Soulez, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Centre hospitalier de l'université de Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

